Ann: Investor presentation - equity raising, page-7

I appreciate your input, but curious as to why you are here then. Genuine question - are you just monitoring SNT's thread to warn off investors?

I have taken into account some slagging off of Garry Phillips that I have read. To be honest I don't know whether it's justified disgruntlement or not.

That said, I think the case seemed pretty compelling for changing PSX (Pharmaxis) to Syntara, and I like what SNT now have to offer over the next 12 months (4 x trials underway, cash runway of 12 months, positive Ph1 results for SNT-5505, Fiona Wood scar treatment recognition, etc), but appreciate that everyone has a different view. Cheers.